Answers are grounded in this paper and cite their sources.
In recent years, patient survival and physicians' ability to predict survival in NSCLC with brain metastases has improved significantly. The updated Lung-molGPA incorporating gene alteration data into the DS-GPA is a user-friendly tool that may facilitate clinical decision making and appropriate stratification of future clinical trials.
No takes yet. Share an insight, caveat, or question.
Sperduto et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: